Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

BRIEF-Acerus Reports Total Q4 Revenue of $0.5 Mln Compared To $2.1 Mln In Q4 2018

Published 2020-03-04, 07:39 a/m
© Reuters.  BRIEF-Acerus Reports Total Q4 Revenue of $0.5 Mln Compared To $2.1 Mln In Q4 2018

March 4 (Reuters) - Acerus Pharmaceuticals Corporation ASP.TO :

* ACERUS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

* ACERUS PHARMACEUTICALS - INCURRED NET LOSS OF $3.9 MILLION OR $0.01 PER SHARE FOR QUARTER COMPARED TO LOSS OF $5.1 MILLION OR $0.02 PER SHARE FOR Q4 2018

* ACERUS PHARMACEUTICALS CORPORATION - TOTAL REVENUE IN QUARTER WAS $0.5 MILLION COMPARED TO $2.1 MILLION IN Q4 2018

* ACERUS PHARMACEUTICALS CORPORATION - ENTERED 2020 WITH SIGNIFICANT CAPITAL ON HAND THAT WILL ENABLE CO TO EXECUTE U.S. GROWTH STRATEGY

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.